Natalizumab treatment reduces endothelial activity in MS patients.
Journal of Neuroimmunology(2010)
Abstract
Vascular cell adhesion molecule-1 a ligand for leukocyte very late activating antigen-4 is a key player in leukocyte extravasation in MS lesions. Natalizumab a monoclonal antibody against VLA-4 blocks this interaction. VCAM-1 and its soluble form are up-regulated during endothelial activation in MS.
MoreTranslated text
Key words
Multiple sclerosis,Natalizumab,Vascular cell adhesion molecule-1,Very late activating antigen-4,Neutralizing antibodies,sVCAM
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined